SecureKloud Tech

- No firmed-up acquisitions disclosed currently; actively exploring acquisition opportunities to cross-sell and upscale platforms. - Healthcare Triangle IPO proceeds are earmarked towards acquisitions. - Future acquisitions or fundraises may include debt funding, leveraging the flexibility of being a NASDAQ-listed company. - Capital raising efforts ongoing for Blockedge (blockchain business), including private placement and convertible note models. - Focus on scaling blockchain and healthcare platforms with potential IPO plans. - Peak R&D investments have been made, primarily in SaaS platform development; R&D expenses expected to reduce to 8-10% of revenue by early 2022. - Investment in sales and marketing to accelerate revenue growth and build a strong sales pipeline. - No specific immediate large capex disclosed; emphasis on driving organic growth through platform deployment and strategic acquisitions.

- Expect revenue growth acceleration in the next 2-3 quarters due to shift from one-time to recurring revenue models, especially SaaS platforms. - Pipeline of orders is strong, with $8 million signed within 40 days in Q3, reflecting growing business opportunities. - Recurring revenue is increasing significantly — from about 10% a few years back to nearly 40% now, targeting ~70% in 3-4 years. - Platforms like Readable.ai and DataEZ have multi-million dollar potential; recurring annuity revenues from data pipeline contracts range $300K-$650K annually per customer. - Margins expected to improve as platform revenues (with ~60% gross margin) grow, with EBITDA margin goal ~20% in 18-24 months. - Geographic expansion planned — currently 90% revenues from U.S., with growth targeted in India, APEC, Europe, and Middle East. - R&D spend to reduce from peak levels, enabling better cost control and margin expansion as revenues grow. - Sales cycle shortening to ~3 months from 6-12 months due to platform subscription models, aiding faster revenue recognition.

- SecureKloud expects revenue growth acceleration and profit margin expansion in the next 2-3 quarters due to a shift from one-time to recurring revenue models. - Recurring revenues have increased from early 20s% to about 40% now, targeting ~70% over the next 3-4 years, improving revenue visibility and stickiness. - Gross margins are currently around 26.3%, expected to rise to ~35% in 3-4 quarters and eventually reach about 50% in 3-4 years. - EBITDA margin is projected around 20% with low or zero debt, enabling significant margin expansion leading to profits and eventual dividend payments within 18-24 months. - R&D expenses have peaked and will reduce to 8-10% of revenue by Q1 2022, improving cost structure and profitability. - New contract signings (e.g., $8M in Q3) and platform adoptions will drive sustainable organic revenue growth. - Growth from $40M to $300M in 4-5 years is envisaged as SaaS adoption peaks and sales conversions increase.

- The Total Contract Value (TCV) is approximately Rs. 350 to Rs. 370 crores and is constantly increasing due to new contracts. - In the recent quarter, an additional $8 million (about Rs. 50-55 crores) worth of business was signed, to be recognized over multiple quarters. - The company has a strong pipeline of orders with high conversion potential. - The shift to recurring revenue from one-time contracts means revenues are recognized over a period, affecting short-term revenue visibility. - Healthcare Triangle, a subsidiary, has a growing recurring revenue portion (from 23% two years ago to 55% now). - Blockchain business is in early stages with 3-4 Proof of Concepts (POCs) ongoing but no large contracts yet. - The company is actively looking at acquisition opportunities to enhance its orderbook.

- No firm acquisition or fundraising is currently finalized or disclosed; announcements will follow as appropriate. - The company is actively looking at acquisition opportunities, especially to cross-sell and upscale platforms. - Any future fundraising, including acquisitions or capital raises, may be via debt or equity depending on market conditions and valuation. - As a NASDAQ-listed company, SecureKloud has multiple fundraising options open including debt, which may be preferred if valuations are high. - The Healthcare Triangle IPO proceeds mentioned were intended partly for acquisitions. - There is ongoing capital raising for Blockedge (Blockchain subsidiary), initially through convertible notes, with potential IPO plans later, though no exact timelines are confirmed. - The company aims to minimize dilution and prefers cost-effective fundraising mechanisms in the US market.